# Tremfya (guselkumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/guselkumab

> The FDA approved Tremfya (guselkumab), sponsored by JOHNSON & JOHNSON (JNJ), on July 13, 2017.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Tremfya (guselkumab) |
| Codes | CNTO1959 |
| Sponsor | JOHNSON & JOHNSON (JNJ) https://sec-api.dev/companies/jnj/catalysts |
| Indications | [Crohn's Disease](https://sec-api.dev/indications/crohn-s-disease), [Crohn Disease](https://sec-api.dev/indications/crohn-disease), [Colitis, Ulcerative](https://sec-api.dev/indications/colitis-ulcerative), Fistulizing Crohns Disease, [Plaque Psoriasis](https://sec-api.dev/indications/plaque-psoriasis) |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### July 13, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761061 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170713, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product TREMFYA (GUSELKUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761061%22

### July 13, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761061 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20200713, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product TREMFYA (GUSELKUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761061%22

### September 11, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761061 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20240911, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product TREMFYA (GUSELKUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761061%22

### March 20, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761061 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20250320, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product TREMFYA (GUSELKUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761061%22

### May 15, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Colitis, Ulcerative.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05242484 (A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05242484

### May 23, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05242471 (A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-05-23 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05242471

### May 30, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Plaque Psoriasis; Scalp Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05272150 (Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-06-24." https://clinicaltrials.gov/study/NCT05272150

### September 19, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761061 SUPPL-26 (Efficacy): submission_status AP, submission_status_date 20250919, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product TREMFYA (GUSELKUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761061%22
- openFDA Drugs@FDA: "BLA761061 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20250926, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product TREMFYA (GUSELKUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761061%22
- openFDA Drugs@FDA: "BLA761061 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20250926, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product TREMFYA (GUSELKUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761061%22

### May 28, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761061 SUPPL-34 (Efficacy): submission_status AP, submission_status_date 20260528, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product TREMFYA (GUSELKUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761061%22

### June 24, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Plaque Psoriasis; Scalp Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05272150 (Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-06-24." https://clinicaltrials.gov/study/NCT05272150?tab=results

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Fistulizing Crohns Disease; Perianal Crohns Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05347095 (A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-25 (ESTIMATED); Lead Sponsor Janssen-Cilag Ltd.." https://clinicaltrials.gov/study/NCT05347095

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Fistulizing Crohns Disease; Perianal Crohns Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05347095 (A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-25 (ESTIMATED); Lead Sponsor Janssen-Cilag Ltd.." https://clinicaltrials.gov/study/NCT05347095

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06408935 (Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-08 (ESTIMATED); Lead Sponsor Janssen-Cilag Ltd.." https://clinicaltrials.gov/study/NCT06408935

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06408935 (Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-08 (ESTIMATED); Lead Sponsor Janssen-Cilag Ltd.." https://clinicaltrials.gov/study/NCT06408935

### Oct 2027 to Jan 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05923073 (A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-27 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05923073

### October 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05923073 (A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-27 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05923073

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Crohn Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07577843 (A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT07577843

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Crohn Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07577843 (A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT07577843

### Aug to Nov 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Colitis, Ulcerative.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07577856 (A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-11 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT07577856

### August 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Colitis, Ulcerative.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07577856 (A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-11 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT07577856

### Nov 2028 to Feb 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Crohn Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07499232 (A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT07499232

### November 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Crohn Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07499232 (A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT07499232

## Same indication

- [ABBV-8736](https://sec-api.dev/pdufa/abbv-8736) (ABBV)
- [Otezla (apremilast)](https://sec-api.dev/pdufa/apremilast) (AMGN)
- [AZD7798](https://sec-api.dev/pdufa/azd7798) (AZN)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Darvadstrocel](https://sec-api.dev/pdufa/darvadstrocel) (TAK)
- [Sotyktu (deucravacitinib)](https://sec-api.dev/pdufa/deucravacitinib) (BMY)
- [Duvakitug](https://sec-api.dev/pdufa/duvakitug) (SNY)
- [Envudeucitinib](https://sec-api.dev/pdufa/envudeucitinib) (ALMS)
- [Etrasimod](https://sec-api.dev/pdufa/etrasimod) (PFE)
- [Guselkumab subcutaneous](https://sec-api.dev/pdufa/guselkumab-subcutaneous) (JNJ)
- [ICOTYDE (icotrokinra)](https://sec-api.dev/pdufa/icotrokinra) (JNJ)
- [Iv tulisokibart](https://sec-api.dev/pdufa/iv-tulisokibart) (MRK)
- [LY4395089](https://sec-api.dev/pdufa/ly4395089) (LLY)
- [Mirikizumab](https://sec-api.dev/pdufa/mirikizumab) (LLY)
- [Open-label envudeucitinib](https://sec-api.dev/pdufa/open-label-envudeucitinib) (ALMS)
- [ORKA-001](https://sec-api.dev/pdufa/orka-001) (ORKA)
- [Orka-001 induction dose](https://sec-api.dev/pdufa/orka-001-induction-dose) (ORKA)
- [ORKA-002](https://sec-api.dev/pdufa/orka-002) (ORKA)
- [Zeposia (ozanimod hydrochloride)](https://sec-api.dev/pdufa/ozanimod) (BMY)
- [Piclidenoson](https://sec-api.dev/pdufa/piclidenoson) (CANF)
- [Skyrizi® (risankizumab)](https://sec-api.dev/pdufa/risankizumab) (ABBV)
- [Risankizumab iv](https://sec-api.dev/pdufa/risankizumab-iv) (ABBV)
- [Risankizumab sc](https://sec-api.dev/pdufa/risankizumab-sc) (ABBV)
- [SAR441566](https://sec-api.dev/pdufa/sar441566) (SNY)
- [TAK-279](https://sec-api.dev/pdufa/tak-279) (TAK)
- [Tapinarof cream, 1%](https://sec-api.dev/pdufa/tapinarof-cream-1) (OGN)
- [Tev-48574 dose regimen a](https://sec-api.dev/pdufa/tev-48574-dose-regimen-a) (TEVA)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)
- [WEZLANA® (ustekinumab)](https://sec-api.dev/pdufa/ustekinumab) (JNJ)
- [Ustekinumab dose based on bsa and body weight](https://sec-api.dev/pdufa/ustekinumab-dose-based-on-bsa-and-body-weight) (JNJ)
- [Entyvio® (vedolizumab)](https://sec-api.dev/pdufa/vedolizumab) (TAK)
- [Vedolizumab iv](https://sec-api.dev/pdufa/vedolizumab-iv) (TAK)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)
- [Zl-1102 1% w/w gel bid for 16 weeks](https://sec-api.dev/pdufa/zl-1102-1-w-w-gel-bid-for-16-weeks) (ZLAB)

Calendar months: [March 2027](https://sec-api.dev/fda-calendar/2027-03), [June 2027](https://sec-api.dev/fda-calendar/2027-06), [October 2027](https://sec-api.dev/fda-calendar/2027-10), [June 2028](https://sec-api.dev/fda-calendar/2028-06), [August 2028](https://sec-api.dev/fda-calendar/2028-08), [November 2028](https://sec-api.dev/fda-calendar/2028-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/guselkumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Tremfya (guselkumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/guselkumab

```bibtex
@misc{secapidev_pdufa_guselkumab_20261116,
  title        = {Tremfya (guselkumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/guselkumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_guselkumab_20261116","title":"Tremfya (guselkumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/guselkumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
